Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Journal of Diabetes ResearchOpen Access

Astragaloside IV Improves Diabetic Kidney Disease by Regulating NLRP3 Inflammasome

View Full Paper
Ask AI
Bookmark
Share

Authors

LZLiping ZhengZKZhao Ke-qinAZAo Zeng

Discussion

Loading...

Member takes

Overview

Review demonstrates how astragaloside IV improves diabetic kidney disease by regulating inflammation and metabolism.

Key Points

  • Astragaloside IV reduces pyroptosis in diabetic kidney disease, highlighting a potential therapeutic pathway.
  • Key mechanisms involve anti‐inflammatory effects, antioxidative stress, and regulation of lipid metabolism.
  • Analysis explores the role of NLRP3 inflammasome in diabetic kidney disease for new treatment strategies.
  • Findings support the potential of natural products in drug development for diabetic kidney disease.

Cite This Study

Zheng et al. (2025) studied this question.

synapsesocial.com/papers/6930dc81ea1aef094cca23fahttps://doi.org/10.1155/jdr/3340719
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Astragaloside IV reduces diabetic kidney injury by inhibiting the PKC/NOX4/MAPK pathway2025
  2. 2Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV.2025
  3. 3Metabolite‐Guided Acetylation Therapy: Astragaloside IV Reverses Diabetic Nephropathy via Gna13‐Driven Purine Metabolic Reprogramming2025 · 7 citations
  4. 4Natural Products as Potential Therapeutic Candidates for Diabetic Kidney Disease: Molecular Mechanisms, Translational Challenges, and Future Prospects2025
  5. 5Therapeutic potential of natural medicines in diabetic kidney disease: restoring lipid homeostasis via lipophagy modulation2025